UB Paderborn / Katalog / Suche / in CDI

Selective targeting of the stress chaperome as a therapeutic strategy

Trends in pharmacological sciences (Regular ed.), 2014-11, Vol.35 (11), p.592-603

2014

Volltextzugriff (PDF)

A Hyperactive Signalosome in Acute Myeloid Leukemia Drives Addiction to a Tumor-Specific Hsp90 Species

Cell reports (Cambridge), 2015-12, Vol.13 (10), p.2159-2173

2015

Volltextzugriff (PDF)

Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions

Expert opinion on investigational drugs, 2014-05, Vol.23 (5), p.611-628

2014

Volltextzugriff (PDF)

Ligand deconstruction: Why some fragment binding positions are conserved and others are not

Proceedings of the National Academy of Sciences - PNAS, 2015-05, Vol.112 (20), p.E2585-E2594

2015

Volltextzugriff (PDF)

Chemical tools for epichaperome-mediated interactome dysfunctions of the central nervous system

Nature communications, 2021-08, Vol.12 (1), p.4669-4669, Article 4669

2021

Volltextzugriff (PDF)

Affinity Purification Probes of Potential Use To Investigate the Endogenous Hsp70 Interactome in Cancer

ACS chemical biology, 2014-08, Vol.9 (8), p.1698-1705

2014

Volltextzugriff (PDF)

Structure–Activity Relationship in a Purine-Scaffold Compound Series with Selectivity for the Endoplasmic Reticulum Hsp90 Paralog Grp94

Journal of medicinal chemistry, 2015-05, Vol.58 (9), p.3922-3943

2015

Volltextzugriff (PDF)

First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer

Clinical cancer research, 2020-10, Vol.26 (19), p.5178-5187

2020

Volltextzugriff (PDF)

The human Aurora kinase inhibitor danusertib is a lead compound for anti-trypanosomal drug discovery via target repurposing

European journal of medicinal chemistry, 2013-04, Vol.62, p.777-784

2013

Volltextzugriff (PDF)

Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias

Blood, 2015-11, Vol.126 (22), p.2479-2483

2015

Volltextzugriff (PDF)

Pharmacological Validation of Trypanosoma brucei Phosphodiesterases B1 and B2 as Druggable Targets for African Sleeping Sickness

Journal of medicinal chemistry, 2011-12, Vol.54 (23), p.8188-8194

2011

Volltextzugriff (PDF)

Repurposing Human PDE4 Inhibitors for Neglected Tropical Diseases. Evaluation of Analogs of the Human PDE4 Inhibitor GSK-256066 as Inhibitors of PDEB1 of Trypanosoma brucei

Chemical biology & drug design, 2015-05, Vol.85 (5), p.549-564

2015

Volltextzugriff (PDF)

Synthesis and assessment of catechol diether compounds as inhibitors of trypanosomal phosphodiesterase B1 (TbrPDEB1)

Bioorganic & medicinal chemistry letters, 2013-11, Vol.23 (21), p.5971-5974

2013

Volltextzugriff (PDF)

Synthesis and evaluation of human phosphodiesterases (PDE) 5 inhibitor analogs as trypanosomal PDE inhibitors. Part 1. Sildenafil analogs

Bioorganic & medicinal chemistry letters, 2012-04, Vol.22 (7), p.2579-2581

2012

Volltextzugriff (PDF)

Synthesis and evaluation of human phosphodiesterases (PDE) 5 inhibitor analogs as trypanosomal PDE inhibitors. Part 2. Tadalafil analogs

Bioorganic & medicinal chemistry letters, 2012-04, Vol.22 (7), p.2582-2584

2012

Volltextzugriff (PDF)

Radiosynthesis of the iodine-124 labeled Hsp90 inhibitor PU-H71

Journal of labelled compounds & radiopharmaceuticals, 2016-03, Vol.59 (3), p.129-132

2016

Volltextzugriff (PDF)

First-in-Human Trial of Epichaperome-Targeted Positron Emission Tomography in Cancer Patients

Clinical cancer research, 2020-05, Vol.26 (19), p.5178-5187

2020

Volltextzugriff (PDF)

Correction: Ligand deconstruction: Why some fragment binding positions are conserved and others are not

Proceedings of the National Academy of Sciences - PNAS, 2015-07, Vol.112 (28), p.E3749-E3749

2015

Volltextzugriff (PDF)

Abstract 2831: Development of selective GRP94 inhibitors for the treatment of cancer

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.2831-2831

2015

Volltextzugriff (PDF)

Repurposing Human PDE 4 Inhibitors for Neglected Tropical Diseases. Evaluation of Analogs of the Human PDE 4 Inhibitor GSK ‐256066 as Inhibitors of PDEB 1 of Trypanosoma brucei

Chemical biology & drug design, 2015-05, Vol.85 (5), p.549-564

2015

Volltextzugriff (PDF)

Synthesis and evaluation of human phosphodiesterases (PDE) 5 inhibitor analogs as trypanosomal PDE inhibitors. 2. Tadalafil analogs

Bioorganic & medicinal chemistry letters, 2012-02, Vol.22 (7), p.2582-2584

2012

Volltextzugriff (PDF)

Synthesis and evaluation of human phosphodiesterases (PDE) 5 inhibitor analogs as trypanosomal PDE inhibitors. 1. Sildenafil analogs

Bioorganic & medicinal chemistry letters, 2012-02, Vol.22 (7), p.2579-2581

2012

Volltextzugriff (PDF)

Design, synthesis & evaluation of human Aurora kinase and phosphodiesterase inhibitors for anti-trypanosomal drug discovery via target repurposing

Ochiana, Stefan O

2013

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Selective targeting of the stress chaperome as a therapeutic strategy

A Hyperactive Signalosome in Acute Myeloid Leukemia Drives Addiction to a Tumor-Specific Hsp90 Species

Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions

Ligand deconstruction: Why some fragment binding positions are conserved and others are not

Chemical tools for epichaperome-mediated interactome dysfunctions of the central nervous system

Affinity Purification Probes of Potential Use To Investigate the Endogenous Hsp70 Interactome in Cancer

Structure–Activity Relationship in a Purine-Scaffold Compound Series with Selectivity for the Endoplasmic Reticulum Hsp90 Paralog Grp94

First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer

The human Aurora kinase inhibitor danusertib is a lead compound for anti-trypanosomal drug discovery via target repurposing

Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias

Pharmacological Validation of Trypanosoma brucei Phosphodiesterases B1 and B2 as Druggable Targets for African Sleeping Sickness

Repurposing Human PDE4 Inhibitors for Neglected Tropical Diseases. Evaluation of Analogs of the Human PDE4 Inhibitor GSK-256066 as Inhibitors of PDEB1 of Trypanosoma brucei

Synthesis and assessment of catechol diether compounds as inhibitors of trypanosomal phosphodiesterase B1 (TbrPDEB1)

Synthesis and evaluation of human phosphodiesterases (PDE) 5 inhibitor analogs as trypanosomal PDE inhibitors. Part 1. Sildenafil analogs

Synthesis and evaluation of human phosphodiesterases (PDE) 5 inhibitor analogs as trypanosomal PDE inhibitors. Part 2. Tadalafil analogs

Radiosynthesis of the iodine-124 labeled Hsp90 inhibitor PU-H71

First-in-Human Trial of Epichaperome-Targeted Positron Emission Tomography in Cancer Patients

Correction: Ligand deconstruction: Why some fragment binding positions are conserved and others are not

Abstract 2831: Development of selective GRP94 inhibitors for the treatment of cancer

Repurposing Human PDE 4 Inhibitors for Neglected Tropical Diseases. Evaluation of Analogs of the Human PDE 4 Inhibitor GSK ‐256066 as Inhibitors of PDEB 1 of Trypanosoma brucei

Synthesis and evaluation of human phosphodiesterases (PDE) 5 inhibitor analogs as trypanosomal PDE inhibitors. 2. Tadalafil analogs

Synthesis and evaluation of human phosphodiesterases (PDE) 5 inhibitor analogs as trypanosomal PDE inhibitors. 1. Sildenafil analogs

Design, synthesis & evaluation of human Aurora kinase and phosphodiesterase inhibitors for anti-trypanosomal drug discovery via target repurposing

Suchergebnisse filtern